Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvation Bio (NUVB)
NYSE:NUVB
Holding NUVB?
Track your performance easily
NUVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $4.16
Previous CloseN/A
Volume977.37K
Average Volume (3M)2.80M
Market Cap
$850.67M
Enterprise Value$88.52M
Total Cash (Recent Filing)$215.75M
Total Debt (Recent Filing)$3.10M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Feb 26, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding336,566,530
10 Day Avg. Volume3,049,311
30 Day Avg. Volume2,802,304
Standard Deviation0.21
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)392.30
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue40.94
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$10.50Price Target Upside337.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Nuvation Bio News
PremiumCompany Announcements
Nuvation Bio’s Q3 2024 Highlights and Future Prospects
PremiumCompany Announcements
Nuvation Bio Announces Philippe Sauvage as New CFOBulls Say, Bears Say
Bulls Say
Efficacy And SafetyTaletrectinib is viewed as a promising agent in the ROS1 landscape due to its competitive efficacy, solid CNS activity, and favorable safety.
Market PenetrationThe updated NCCN guidelines now recommend starting patients on a ROS1-targeted TKI like taletrectinib if a ROS1 rearrangement is discovered, supporting potential market penetration.
Regulatory ProgressNuvation announced that the FDA has accepted the company’s New Drug Application (NDA) for taletrectinib.
Bears Say
Market CompetitionThere is a risk of poorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.
Product CommercializationThere is a potential risk of poorer-than-anticipated commercial uptake of products due to competition or other market factors.
Regulatory ApprovalRisks include failure to obtain timely approval for the company's pipeline candidates, particularly taletrectinib.
---
Ownership Overview
27.30% Insiders
10.34% Mutual Funds
0.04% Other Institutional Investors
54.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $1.52 and its highest was $4.16 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $850.67M.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Feb 26, 2025 which is in 25 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Nov 06, 2024. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.126 by -$0.024.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.13.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 336,566,530 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.126. Following the earnings report the stock price went up 3.15%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
---
Nuvation Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (337.50% Upside)
$10.50 (337.50% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $162.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.65%
12-Months-Change
Fundamentals
Return on Equity
-95.54%
Trailing 12-Months
Asset Growth
-9.40%
Trailing 12-Months
Company Description
Nuvation Bio
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
---
NUVB Stock 12 Month Forecast
Average Price Target
$10.50
▲(337.50% Upside)
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Blueprint Medicines
―
Crispr Therapeutics AG
―
Immatics
―
Best Analysts Covering NUVB
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
+7.70%
reiterated a buy rating 25 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +7.70% per trade.
---